Cancer progression in the kidney and prostate: Vital roles of sphingolipids in chemotherapy

Urology

Volumn 60, Issue 4, 2002, Pages 562-568

  Radin, Norman S ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Reprint Requests: Norman Radin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DECANOYLAMINO 3 MORPHOLINO 1 PHENYL 1 PROPANOL; ANTIANDROGEN; CAVEOLIN 1; CERAMIDE DERIVATIVE; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; ESTRADIOL; REACTIVE OXYGEN METABOLITE; SPHINGOLIPID; TESTOSTERONE;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CELL PROLIFERATION; HUMAN; KIDNEY CARCINOMA; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GLUTATHIONE; GROWTH SUBSTANCES; HUMANS; KIDNEY NEOPLASMS; MALE; PROSTATIC NEOPLASMS; SPHINGOLIPIDS; TESTOSTERONE; VINBLASTINE;

EID: 0036774169     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01755-7     Document Type: Review

References (47)

1. Hannun Y.A., Luberto C., Argraves K.M. Enzymes of sphingolipid metabolism from modular to integrative signaling. Biochemistry. 40:2001;4893-4903.
2. Riley R.T., Enongene E., Voss K.A., et al. Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis. Environ Health Perspect. 109:(suppl 2):2001;301-308.
3. Levade T., Auge N., Veldman R.J., et al. Sphingolipid mediators in cardiovascular cell biology and pathology. Circ Res. 89:2001;957-968.
4. Olivera A., Spiegel S. Sphingosine kinase a mediator of vital cellular functions . Prostaglandins. 64:2001;123-134.
5. Senchenkov A., Litvak D.A., Cabot M.C. Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Natl Cancer Inst. 93:2001;347-357.
6. Shayman J.A. Sphingolipids. Kidney Int. 58:2000;11-26.
7. Chatterjee S. Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol. 18:1998;1523-1533.
8. Radin N.S. Killing cancer cells by poly-drug elevation of ceramide - a hypothesis whose time has come? Eur J Biochem. 268:2001;193-204.
9. Radin N.S. Apoptotic death by ceramide will the real killer please stand up? Med Hypoth. 57:2001;96-100.
10. Radin N.S. The development of aggressive cancer: a possible role for sphingolipids. Cancer Invest. 20:2002.
11. Lavie Y., Cao H., Bursten S.L., et al. Accumulation of glucosylceramides in multidrug resistant cancer cells. J Biol Chem. 271:1996;19530-19536.
12. Luberto C., Hannun Y.A. Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C? J Biol Chem. 273:1998;14550-14559.
13. Hoon D.S.B., Okun E., Neuwirth H., et al. Aberrant expression of gangliosides in human renal cell carcinomas. J Urol. 150:1993;2013-2018.
14. Zador I.Z., Deshmukh G.D., Kunkel R., et al. A role for glycosphingolipid accumulation in the renal hypertrophy of streptozotocin-induced diabetes mellitus. J Clin Invest. 91:1993;797-803.
15. El-Khatib M., Radin N.S., Shayman J.A. Glycosphingolipid synthesis and proliferation in a renal cell line grown in high glucose. Am J Physiol. 270:1996;F476-F484.
16. Radin N.S. Chemotherapy by slowing glucosphingolipid synthesis. Biochem Pharmacol. 57:1999;589-595.
17. Shukla A., Shukla G.S., Radin N.S. Control of kidney size by sex hormones possible involvement of glucosylceramide . Am J Physiol. 262:1992;F24-F29.
18. Johnston E.M., McIntyre L.M., Hoff J.A. The effect of orchiectomy on lung cancer survival. Anticancer Res. 19:1999;5567-5570.
19. Iwamoto T., Fukumoto S., Kanaoka K., et al. Lactosylceramide is essential for the osteoclastogenesis mediated by macrophage-colony-stimulating factor and receptor activator of nuclear factor-kappa B ligand. J Biol Chem. 276:2001;46031-46038.
20. Dhingra K. Selective estrogen receptor modulation the search for an ideal hormonal therapy for breast cancer . Cancer Invest. 19:2001;649-659.
21. Takeda H., Ozaki K., Yasuda H., et al. Sphingomyelinase and ceramide inhibit formation of F-actin ring in and bone resorption by rabbit mature osteoclasts. FEBS Lett. 422:1998;255-258.
22. de la Taille A., Chen M.W., Shabsigh A., et al. Fas antigen/CD-95 upregulation and activation during castration-induced regression of the rat ventral prostate gland. Prostate. 40:1999;89-96.
23. Seelan R.S., Qian C., Yokomizo A., et al. Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer. 29:2000;137-146.
24. Hara T., Kosaka N., Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 39:1998;990-995.
25. Dahiya R., Boyle B., Goldberg B.C., et al. Metastasis-associated alterations in phospholipids and fatty acids of human prostatic adenocarcinoma cell lines. Biochem Cell Biol. 70:1992;548-554.
26. Abe A., Radin N.S., Shayman J.A., et al. Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res. 36:1995;611-621.
27. Shirahama T., Sakakura C., Sweeney E.A., et al. Sphingosine induces apoptosis in androgen-independent human prostatic carcinoma DU-145 cells by suppression of bcl-XL gene expression. FEBS Lett. 407:1997;97-100.
28. Kojima H., Endo K., Moriyama H., et al. Abrogation of mitochondrial cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem. 273:1998;16647-16650.
29. Cuvillier O., Levade T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood. 98:2001;2828-2836.
30. Nasu Y., Timme T.L., Yang G., et al. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med. 4:1998;1062-1106.
31. Borg A.G., Burgess R., Green L.M., et al. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol. 103:1998;1083-1091.
32. Rosenwald A.G., Pagano R.E. Effects of the glycosphingolipid synthesis inhibitor, PDMP, on lysosomes in cultured cells. J Lipid Res. 35:1994;1232-1240.
33. Thompson T.C. Metastasis-related genes in prostate cancer the role of caveolin-1 . Cancer Metastasis Rev. 17:1998-1999;439-442.
34. y glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma. Int J Oncol. 19:2001;941-946.
35. Inokuchi J., Jimbo M., Momosaki K., et al. Inhibition of experimental metastasis of murine Lewis lung carcinoma by an inhibitor of glucosylceramide synthase and its possible mechanism of action. Cancer Res. 50:1990;6731-6737.
36. Deng W., Li R.X., Ladisch S. Influence of cellular ganglioside depletion on tumor formation. J Nat Cancer Inst. 92:2000;912-917.
37. Shimura S., Yang G., Ebara S., et al. Reduced infiltration of tumor-associated macrophages in human prostate cancer association with cancer progression . Cancer Res. 60:2000;5857-5861.
38. Kanto T., Kalinski P., Hunter O.C., et al. Ceramide mediates tumor-induced dendritic cell apoptosis. J Immunol. 167:2001;3773-3784.
39. Shukla G.S., Shukla A., Radin N.S. Gangliosides inhibit glucosylceramide synthase possible role in ganglioside therapy . J Neurochem. 56:1991;2125-2132.
40. Abe A., Gregory S., Lee L., et al. Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest. 105:2000;1563-1571.
41. Ruggieri S., Mugnai G., Mannini A., et al. Lipid charac-teristics in metastatic cells. Clin Exp Metastasis. 17:1999;271-276.
42. Garzotto M., Haimovitz-Friedman A., Liao W.C., et al. Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res. 59:1999;5194-5201.
43. Liu B., Andrieu-Abadie N., Levade T., et al. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem. 273:1998;11313-11320.
44. Davis M.A., Flaws J.A., Young M., et al. Effect of ceramide on intracellular glutathione determines apoptotic or necrotic cell death of JB6 tumor cells. Toxicol Sci. 53:2000;48-55.
45. Riboni L., Viani P., Bassi R., et al. Basic fibroblast growth factor-induced proliferation of primary astrocytes - evidence for the involvement of sphingomyelin biosynthesis. J Biol Chem. 276:2001;12797-12804.
46. Boldin S.A., Futerman A.H. Up-regulation of glucosylceramide synthesis upon stimulation of axonal growth by basic fibroblast growth factor - evidence for post-translational modification of glucosylceramide synthase. J Biol Chem. 275:2000;9905-9909.
47. D'Amico A.V., Schultz D., Loffredo M., et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 284:2000;1280-1283.